This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Radius Health Past Earnings Performance
Past criteria checks 0/6
Key information
28.6%
Earnings growth rate
30.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 35.3% |
| Return on equity | n/a |
| Net Margin | -30.7% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Radius Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 223 | -69 | 129 | 121 |
| 31 Mar 22 | 217 | -73 | 127 | 122 |
| 31 Dec 21 | 230 | -70 | 130 | 131 |
| 30 Sep 21 | 228 | -76 | 138 | 128 |
| 30 Jun 21 | 249 | -60 | 134 | 134 |
| 31 Mar 21 | 247 | -87 | 140 | 151 |
| 31 Dec 20 | 239 | -109 | 143 | 159 |
| 30 Sep 20 | 232 | -113 | 144 | 158 |
| 30 Jun 20 | 200 | -136 | 148 | 149 |
| 31 Mar 20 | 191 | -128 | 150 | 131 |
| 31 Dec 19 | 173 | -133 | 155 | 115 |
| 30 Sep 19 | 152 | -149 | 163 | 104 |
| 30 Jun 19 | 133 | -169 | 170 | 100 |
| 31 Mar 19 | 115 | -203 | 179 | 99 |
| 31 Dec 18 | 99 | -221 | 186 | 98 |
| 30 Sep 18 | 72 | -251 | 193 | 97 |
| 30 Jun 18 | 58 | -259 | 197 | 91 |
| 31 Mar 18 | 37 | -259 | 199 | 84 |
| 31 Dec 17 | 22 | -254 | 189 | 81 |
| 30 Sep 17 | 14 | -236 | 167 | 82 |
| 30 Jun 17 | 1 | -224 | 138 | 89 |
| 31 Mar 17 | 0 | -199 | 104 | 97 |
| 31 Dec 16 | 0 | -183 | 80 | 105 |
| 30 Sep 16 | 0 | -163 | 62 | 104 |
| 30 Jun 16 | 0 | -145 | 51 | 95 |
| 31 Mar 16 | 0 | -125 | 40 | 84 |
| 31 Dec 15 | 0 | -102 | 31 | 68 |
Quality Earnings: RDUS is currently unprofitable.
Growing Profit Margin: RDUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.